Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Industry FTC Finds Only 1 Violation of New Rules on Settai in FY2012 Following Their Introduction
June 21, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 2: Explanations to the World Urged
June 21, 2013
- MSD Revives “US Training” Program to Enhance Skills of Outstanding MRs
June 21, 2013
- Baxter Receives Approval for Cell-Based H5N1 Vaccine
June 20, 2013
- Daiichi Sankyo Files NDA for Next Mainstay Product Prasugrel in Japan
June 20, 2013
- AZ, BMKK Aim to Develop Market for Bydureon as Drug before Insulin
June 20, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 1: A Blurred Line
June 20, 2013
- Takeda’s 3 Nesina Family Drugs Make US Debut
June 19, 2013
- MSD to Continue Efforts for HPV Vaccine Recommendation
June 19, 2013
- Novartis Pharma to Voluntarily Refrain from Participation in JPMA’s Board of Directors Meeting
June 19, 2013
- Chairman Kato Resigns, to Move to Specially Appointed Professor Position at University of Tokyo: AZ
June 19, 2013
- GSK Says No Evidence Shows Causal Link between HPV Vaccines and Serious Adverse Events
June 18, 2013
- Shionogi Signs MOU on R&D with Six Universities in Ireland
June 18, 2013
- Eisai to Expand Packaging Facility at UK Plant, Eying Lenvatinib Launch
June 18, 2013
- Takeda, Pfizer Settle Protonix Patent Lawsuit with Teva, Sun for US$2.15 Billion
June 17, 2013
- Stroke Prevention Effects Confirmed in PIII Study of Pradaxa in Asia: BI Japan
June 17, 2013
- Daiichi Sankyo, JICA Start Technical Cooperation on MR Vaccine Production in Vietnam
June 17, 2013
- Sanofi Ends Development on Iniparib, Otamixaban
June 14, 2013
- ARBs Still Best Sellers in FY2012 Sales Ranking, Januvia Ranks in Top 10 after only 3 Years of Launch
June 14, 2013
- Nippon Shinyaku’s Licensee Taejoon Pharm Launches Gaslon N-OD Tablets in South Korea
June 14, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…